Compounders Research Compare

Atrium Therapeutics, Inc.(RNA)

Biotechnology · San Diego, CA

$7.99+0.02 (+0.25%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

San Diego, CA

511 employees

www.atriumtherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Kathleen Gallagher

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T22:52:35.176Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:52:35.176Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 136,674,088
Total debt · period ending 2026-06-30: 1,683,000
Cash · period ending 2026-06-30: 72,645,000
TTM operating EBITDA · period ending 2026-06-30: -95,711,000

FMP input reference: 87d00981f6afc2d6fb42b8babadf75d30967326f42a5e12d4c63051d6ceded83

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

RNA EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

RNA Competitors' EV/EBITDA Ratio

Atrium Therapeutics, Inc.

Current

Market Cap

$136.67M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Organigram Global Inc.

Market Cap

$136.57M

EV/EBITDA Ratio

10.66x

TTM Avg

444.93x

3Y Avg

542.94x

5Y Avg

476.27x

KORU Medical Systems, Inc.

Market Cap

$137.80M

EV/EBITDA Ratio

N/A

TTM Avg

693.21x

3Y Avg

347.06x

5Y Avg

258.50x

Immuneering Corporation

Market Cap

$139.04M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Alpha Cognition Inc

Market Cap

$139.47M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Sutro Biopharma, Inc.

Market Cap

$139.84M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Freenome, Inc.

Market Cap

$133.45M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LifeMD, Inc.

Market Cap

$132.03M

EV/EBITDA Ratio

N/A

TTM Avg

53.44x

3Y Avg

53.44x

5Y Avg

53.44x

AirSculpt Technologies, Inc.

Market Cap

$131.21M

EV/EBITDA Ratio

430.26x

TTM Avg

352.35x

3Y Avg

117.66x

5Y Avg

91.76x

Health Catalyst, Inc.

Market Cap

$130.79M

EV/EBITDA Ratio

74.38x

TTM Avg

73.16x

3Y Avg

73.16x

5Y Avg

73.16x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Atrium Therapeutics, Inc. (RNA)	$136.67M	N/A	N/A	N/A	N/A
Organigram Global Inc. (OGI)vs ›	$136.57M	10.66x	444.93x	542.94x	476.27x
KORU Medical Systems, Inc. (KRMD)vs ›	$137.80M	N/A	693.21x	347.06x	258.50x
Immuneering Corporation (IMRX)vs ›	$139.04M	N/A	N/A	N/A	N/A
Alpha Cognition Inc (ACOG)vs ›	$139.47M	N/A	N/A	N/A	N/A
Sutro Biopharma, Inc. (STRO)vs ›	$139.84M	N/A	N/A	N/A	N/A
Freenome, Inc. (FRNM)vs ›	$133.45M	N/A	N/A	N/A	N/A
LifeMD, Inc. (LFMD)vs ›	$132.03M	N/A	53.44x	53.44x	53.44x
AirSculpt Technologies, Inc. (AIRS)vs ›	$131.21M	430.26x	352.35x	117.66x	91.76x
Health Catalyst, Inc. (HCAT)vs ›	$130.79M	74.38x	73.16x	73.16x	73.16x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics